search
Back to results

Antibiotic Prophylaxis in Gynecologic Laparoscopy

Primary Purpose

Infection Secondary to Surgical Procedure

Status
Completed
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
gynecologic laparoscopy
Cefazolin
Placebo
Sponsored by
Universidade do Vale do Sapucai
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Infection Secondary to Surgical Procedure focused on measuring laparoscopy, surgical wound infection, antibiotic prophylaxis, gynecologic surgical procedures

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • patients with gynecologic disease, undergoing gynecologic laparoscopy without opening hollow viscera.

Exclusion Criteria:

  • body mass index over 30 Kg/m2
  • smoking
  • diabetes type I or II with glycated hemoglobin exceeding 6.5%
  • patients who are at surgical risk classification of the American Society of Anesthesiologists(ASA) as ASA III or higher
  • refusal to participate
  • postoperative antibiotic therapy for another indication clinical complication

Sites / Locations

  • Hospital das Clinicas Samuel Libanio
  • Hospital e Maternidade Santa Paula

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Active Comparator

Arm Label

Placebo

Cefazolin

Arm Description

Patients in this arm will receive intravenous sterile saline 30 minutes before the gynecologic laparoscopy.

Patients in this arm will receive intravenous cephazolin 1g, 30 minutes before the gynecologic laparoscopy.

Outcomes

Primary Outcome Measures

Surgical site infection
Patients are followed weekly by a masked surgeon in regard to surgical site infecton (SSI), until the 30th postoperative day. Centers for Disease Control and Prevention's (CDC) criteria and classification were adopted.

Secondary Outcome Measures

Full Information

First Posted
November 18, 2013
Last Updated
April 24, 2015
Sponsor
Universidade do Vale do Sapucai
search

1. Study Identification

Unique Protocol Identification Number
NCT01991834
Brief Title
Antibiotic Prophylaxis in Gynecologic Laparoscopy
Official Title
Antibiotic Prophylaxis in Gynecologic Laparoscopy
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
March 2015 (Actual)
Study Completion Date
April 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidade do Vale do Sapucai

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Laparoscopy is a surgical procedure indicated for most gynecological pathologies and presents numerous advantages over laparotomy, among them lower rates of surgical site infection and less comorbidity feverish. Despite this, the use of antibiotic prophylaxis is widely accepted and performed by most gynecologists. However, there isn't literature evidence to support the routine use of antibiotics in the prophylaxis of wound infection on laparoscopic pelvic surgery .Therefore, this study will evaluate the need for the use of antibiotic prophylaxis in gynecological laparoscopies not including opening hollow viscera.
Detailed Description
It is a clinical, prospective, double-blind, randomized study. 114 women with gynecologic disease, in which there is indication of laparoscopic surgical approach, will be consecutively select. These women will be allocated in two arms, control and study, where control group will use placebo and study will receive intravenous cephazolin. These patients will be followed for 30 days according to Centers for Disease Control and Prevention criteria.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection Secondary to Surgical Procedure
Keywords
laparoscopy, surgical wound infection, antibiotic prophylaxis, gynecologic surgical procedures

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
114 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Patients in this arm will receive intravenous sterile saline 30 minutes before the gynecologic laparoscopy.
Arm Title
Cefazolin
Arm Type
Active Comparator
Arm Description
Patients in this arm will receive intravenous cephazolin 1g, 30 minutes before the gynecologic laparoscopy.
Intervention Type
Procedure
Intervention Name(s)
gynecologic laparoscopy
Other Intervention Name(s)
pelvic laparoscopy, gynecologic laparoscopic surgery
Intervention Description
Gynecological laparoscopy without opening hollow viscera.
Intervention Type
Drug
Intervention Name(s)
Cefazolin
Other Intervention Name(s)
Cephazolin, Cefazoline, Cephazolin Sodium for Injection, Kefzol
Intervention Description
Intravenous administration of 1 g of cefazolin
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
placebo treatment
Intervention Description
Intravenous administration of saline sterile solution
Primary Outcome Measure Information:
Title
Surgical site infection
Description
Patients are followed weekly by a masked surgeon in regard to surgical site infecton (SSI), until the 30th postoperative day. Centers for Disease Control and Prevention's (CDC) criteria and classification were adopted.
Time Frame
30 days

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: patients with gynecologic disease, undergoing gynecologic laparoscopy without opening hollow viscera. Exclusion Criteria: body mass index over 30 Kg/m2 smoking diabetes type I or II with glycated hemoglobin exceeding 6.5% patients who are at surgical risk classification of the American Society of Anesthesiologists(ASA) as ASA III or higher refusal to participate postoperative antibiotic therapy for another indication clinical complication
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Fabiola SM Campos, MD
Organizational Affiliation
Universidade do Vale do Sapucai
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Daniela F Veiga, MD, PhD
Organizational Affiliation
Universidade do Vale do Sapucai
Official's Role
Study Chair
Facility Information:
Facility Name
Hospital das Clinicas Samuel Libanio
City
Pouso Alegre
State/Province
Minas Gerais
ZIP/Postal Code
37550-000
Country
Brazil
Facility Name
Hospital e Maternidade Santa Paula
City
Pouso Alegre
State/Province
Minas Gerais
ZIP/Postal Code
37550-000
Country
Brazil

12. IPD Sharing Statement

Learn more about this trial

Antibiotic Prophylaxis in Gynecologic Laparoscopy

We'll reach out to this number within 24 hrs